ABSTRACT
Objetivos Describir la experiencia inicial en el uso de un sistema de biopsia por vacío con guía estereotáxica digital para lesiones mamarias. Material y método Se evaluaron retrospectivamente las biopsias bajo estereotaxia mamográfica con sistema de vacío (bav) realizadas en el Centro de Imagenología Mamaria (imad) de la ciudad de Bahía Blanca desde marzo de 2016 a julio de 2017. En el período analizado, se recibieron 329 pedidos de punción, de los cuales 112 correspondieron a biopsias bajo estereotaxia mamográfica con sistema de vacío y 217 a biopsias bajo ecografía. Se realizaron 99/112 (89%) bav, no pudiéndose completar el procedimiento en 13/112 (11%) de los casos. Resultados Se obtuvieron los siguientes resultados patológicos: 20% (20/99) Maligno, 7% (7/99) Alto riesgo y 73% (72/99) Benigno. Se produjeron complicaciones leves que no requirieron ningún tipo de tratamiento posterior en el 8% de los casos: 7/99 reacción vasovagal y 1/99 dolor que dificultó el procedimiento, aunque en todos los casos se pudo finalizar el mismo. Conclusiones Se diagnosticaron lesiones malignas o de alto riesgo en el 27% de los procedimientos realizados.
Objectives To describe our initial experience with vacuum assisted breast biopsies under stereotactic guidance for non-palpable lesions. Materials and method We retrospectively review the vacuum assisted breast biopsies performed at Centro de Imagenología Mamaria (imad) between march 2016 and july 2017. 329 patients requested a breast biopsy. Of them, 112 were vacuum assisted biopsies under stereotactic guidance and 217 were ultrasound guided. We succesfully completed 99/112 (89%) of vacuum assisted biopsies, not being able to reach the target in the remaining 11%. Results The following pathological results were obtained: 20% (20/99) Malignant, 7% (7/99) High risk and 73% (72/99) Benign lesions. Minor complications, which did not require any further treatment, occurred in 8% of cases: 7/99 vasovagal reactions, 1/99 pain during the procedure. Conclusions Malignant and high-risk lesions were diagnosed in 27% of the procedures performed.
Subject(s)
Humans , Female , Breast Neoplasms , Biopsy , RadiosurgeryABSTRACT
Sphingosine kinase-1 (SPHK1) modulates the proliferation, apoptosis and differentiation of keratinocytes through the regulation of ceramide and sphingosine-1-phosphate levels. However, studies on the expression of SPHK1 in human head and neck squamous cell carcinoma (HNSCC) specimens are lacking. Therefore, the aim of the present work was to evaluate SPHK1 expression in human primary HNSCCs and to correlate the results with clinical and anatomopathological parameters. We investigated the expression of this protein by immunohistochemistry performed in tissue microarrays of HNSCC and in an independent cohort of 37 paraffin-embedded specimens. SPHK1 expression was further validated by real-time PCR performed on laser capture-microdissected tissue samples. The positive rate of SPHK1 protein in the cancerous tissues was significantly higher (74%) than that in the nontumor oral tissues (23%), and malignant tissues showed stronger immunoreactivity for SPHK1 than normal matching samples. These results were confirmed by real-time PCR quantification of SPHK1 mRNA. Interestingly, the positive expression of SPHK1 was associated with shorter patient survival time (Kaplan-Meier survival curves) and with the loss of p21 expression. Taken together, these results demonstrate that SPHK1 is upregulated in HNSCC and provide clues of the role SPHK1 might play in tumor progression.